🔗 Share this article

Given that the US proceeds with sweeping revisions to its immunization schedules, one figure appears somewhat surprisingly: Tracy Beth Høeg, a US-based sports physician and public health researcher who rose to prominence by questioning Covid vaccines throughout the global health crisis and has zeroed in on possible deaths after COVID-19 vaccination in her recent time at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Vaccine Schedule

Agency leaders were set to announce major changes to the childhood vaccination calendar in December, aligning the US with Denmark’s immunization schedule, it is understood – a substantial departure that would put the US out of step with much of the international standard with insufficient data for public health gain. The planned update has been pushed back until the next year.

Rather than the top vaccines chief, Dr. Høeg is scheduled to address the audience at the meeting. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth appointee to run the office this calendar year.

Consolidating Power at the Agency

This interim role may indicate a strengthened alliance between the drug and biologics branches as Høeg and Prasad strengthen their influence at the FDA – and it suggests a greater focus upon dismantling already-approved vaccines at the FDA.

The new acting director has often pushed for ending certain pediatric shot schedules in the US to become more in line with Denmark, a society with comprehensive healthcare and a citizenry roughly the size of Wisconsin’s.

To date statements, she has persisted in emphasizing on vaccination policy – typically the responsibility of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Doubts Over Background

Høeg has little discernible background in pharmaceutical research, regulation or management, which has been customary for former directors of the CBER. She has been employed at the FDA as a senior adviser to the FDA chief and CBER since earlier this year.

“She doesn’t seem to have the necessary background” for leading the CDER, said Jonathan Howard. “She has not conducted a clinical trial. She is not versed in managing a large organization. She is not an expert in industry regulation.”

Previous heads of CBER would “be deeply familiar with legal statutes and the underlying principles of medication creation”, said Janet Woodcock. “Frankly, she has not acquired the kind of background that previous people who ran CBER have had.”

CDER has an enormous range of responsibilities at the FDA, the former commissioner stated.

“Many people just zeroes in on the novel medication approvals, but the off-patent medication office clears a multitude of generic medications. There is also a biosimilars division, non-prescription drug unit and other areas, and every single one need to be looked after,” she explained. “The responsibility you neglect, that is precisely what that I always told people is going to bite you.”

Furthermore, a significant leadership aspect to the role, which manages over 5,000 employees. “It is a enormous management job, if you execute it properly,” she added.

Response and Disputed Programs

Regarding concerns about Høeg’s fitness for the role and whether this assignment signifies greater collaboration among FDA leaders on immunizations, a representative said that the “questions rely on incorrect presumptions”.

“This background aligns with the duties of her job,” the spokesperson explained, citing the months Dr. Høeg spent counseling the agency head on “pharmaceutical safety and approval science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Dr. Høeg inherits the commissioner’s recently launched expedited review system, a disputed expedited therapy clearance system that reportedly troubled her predecessors. “By what process are these therapies being picked for this voucher program? Who takes the calls?” Howard asked. “There’s a lot of lack of transparency going on at the FDA right now.”

In general, he remarked, “the agency appears to be shifting towards less stringent oversight of all drugs, aside from shots.”

Public Track Record on Immunizations

Regarding immunizations, Dr. Høeg has a more documented, if concerning, track record, Howard observe. She authored a analysis using non-validated volunteer-provided data to determine the incidence of myocarditis following Covid vaccination. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccinations are riskier than they are.

Part of her “policy goals” for the incoming administration encompassed altering rules for new vaccines and halting “optional” immunizations, she stated after the election on a podcast. At the agency, Høeg has according to sources floated the idea of preventing adolescent males from getting COVID-19 vaccines.

“She is an all-around ideologue who begins with her conclusions and works backwards to retrofit the evidence in a highly disingenuous, fraudulent way,” Howard said.

Taking Control and a “Revenge Tour”

Høeg aligned with fellow dissenters, {like|